2. Neogi T., Jansen T., Dalbeth N. et al. 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1789–98. https://dx.doi.org/10.1136/annrheumdis-2015-208237.

3. National Institute for Health and Care Excellence (NICE). Gout: Diagnosis and management. NICE guideline. 2022. URL: https://www.nice.org.uk/guidance/ng219/resources/gout-diagnosis-and-management-pdf-66143783599045 (date of access – 01.10.2023).

4. FitzGerald J.D., Dalbeth N., Mikuls T. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020; 72(6): 744–60. https://dx.doi.org/10.1002/acr.24180.

5. Choi H.K., Soriano L.C., Zhang Y., Rodríguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ. 2012; 344: d8190. https://dx.doi.org/10.1136/bmj.d8190.

6. Ogata N., Fujimori S., Oka Y., Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010; 29(4–6): 321–24. https://dx.doi.org/10.1080/15257771003741323.

7. Derosa G., Maffioli P., Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015: 102: 63–70. https://dx.doi.org/10.1016/j.phrs.2015.09.012.

8. Gow P. Treating gout in patients with comorbidities. Int J Clin Rheumtol. 2011; 6(6): 625–33. https://dx.doi.org/10.2217/ijr.11.63.

9. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(S1): 1–29.

10. Terkeltaub R.A., Furst D.E., Bennett K. et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62(4): 1060–68. https://dx.doi.org/10.1002/art.27327.

11. Stamp L.K., Taylor W.J., Jones P.B. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64(8): 2529–36. https://dx.doi.org/10.1002/art.34488.

12. Stamp L.K., O"Donnell J.L., Zhang M. et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011; 63(2): 412–21. https://dx.doi.org/10.1002/art.30119.

13. Chao J., Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr. Rheumatol. Rep. 2009; 11(2): 135–40. https://dx.doi.org/10.1007/s11926-009-0019-z.

14. Schumacher H.R. Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double blind, parallel-group trial. Arthritis Rheum. 2008; 59(11): 1540–48. https://dx.doi.org/10.1002/art.24209.

15. Mackenzie I.S., Ford I., Nuki G. et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745–57. https://dx.doi.org/10.1016/S0140-6736(20)32234-0.

16. Becker M.A., Schumacher H.R., MacDonald P.A. et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36(6): 1273–82. https://dx.doi.org/10.3899/jrheum.080814.